About Axion Biosystems
Axion Biosystems is a company based in Atlanta (United States) founded in 2007 was acquired by Summa Equity in July 2021. Axion Biosystems has raised $20.31 million across 14 funding rounds from investors including HHS, GRA Venture Fund and Summa Equity. Axion Biosystems has completed 1 acquisition, including msolv. Axion Biosystems offers products and services including MEA Maestro Pro, Omni Pro 12, and Corning Cell Counter. Axion Biosystems operates in a competitive market with competitors including 10X Genomics, Mission Bio, Cellares, LUMICKS and LevitasBio, among others.
- Headquarter Atlanta, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Axion Biosystems, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.31 M (USD)
in 14 rounds
-
Latest Funding Round
$2.82 M (USD), Grant
Jan 01, 2020
-
Investors
HHS
& 2 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Summa Equity
(Jul 15, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Axion Biosystems
Axion Biosystems offers a comprehensive portfolio of products and services, including MEA Maestro Pro, Omni Pro 12, and Corning Cell Counter.
Monitors electrical activity in neurons and cardiomyocytes in real time.
Provides automated live-cell imaging for cellular biology analysis.
Automates brightfield and fluorescent counting of cells and organoids.
People of Axion Biosystems
Unlock access to complete
Unlock access to complete
Funding Insights of Axion Biosystems
Axion Biosystems has successfully raised a total of $20.31M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $2.82 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Axion Biosystems
Axion Biosystems has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, GRA Venture Fund and Summa Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed & early stage sector-agnostic venture capital firm funding companies in the US
|
Locked | Locked | Locked | |
|
Summa Equity is focused on thematic and impact investments.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Axion Biosystems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Axion Biosystems
Axion Biosystems has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include msolv.
Investment portfolio details for Axion Biosystems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Advanced laser and inkjet systems for manufacturing are developed.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Axion Biosystems
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Axion Biosystems
Detailed financials for Axion Biosystems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Axion Biosystems Comparisons
Peer comparison for Axion Biosystems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Axion Biosystems
Axion Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Cellares, LUMICKS and LevitasBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| Locked | Locked | Locked |
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
|
|
| Locked | Locked | Locked |
Medical devices for cell-based therapy manufacturing are produced.
|
|
| Locked | Locked | Locked |
Optical tweezers instruments for single-molecule analysis are manufactured.
|
|
| Locked | Locked | Locked |
Single-cell imaging platform developed via magnetic levitation technology.
|
|
| Locked | Locked | Locked |
Cell-based phenotyping technologies and assays are provided for microbial analysis.
|
Detailed competitors of Axion Biosystems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Axion Biosystems
Complete news archive for Axion Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axion Biosystems
Axion Biosystems was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Axion Biosystems is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Axion Biosystems is a funded company, having raised a total of $20.31M across 14 funding rounds to date.
Axion Biosystems was founded in 2007 in Atlanta, United States, within the biotechnology sector. Multi-electrode array technology is provided by the company to support cellular analysis in research, clinical, and drug discovery applications. Operations include the development of single-well systems, stimulating and recording channels, multi-well systems, and integrated circuits designed to reduce stimulation artifacts. Focus is placed on enabling precise data collection for scientific and therapeutic purposes.
Axion Biosystems's top competitors include 10X Genomics, Mission Bio and Cellares.
Axion Biosystems offers MEA Maestro Pro, Omni Pro 12, and Corning Cell Counter.
Axion Biosystems has made 1 acquisition, including msolv.
Axion Biosystems has 3 investors. Key investors include HHS, GRA Venture Fund, and Summa Equity.